Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2019
Price : $35 *
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms OBERAL
- 13 Jun 2019 Planned End Date changed from 30 Oct 2019 to 30 May 2020.
- 13 Jun 2019 Planned primary completion date changed from 31 Mar 2019 to 1 Nov 2019.
- 13 Jun 2019 Status changed from recruiting to active, no longer recruiting.